These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7459218)

  • 1. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):831-40. PubMed ID: 7459218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults.
    Buckman R; Cuzick J; Galton DA
    Br J Haematol; 1982 Dec; 52(4):589-99. PubMed ID: 6958312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
    Cuzick J; Cooper EH; MacLennan IC
    Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report on the second myelomatosis trial after five years of follow-up. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):813-22. PubMed ID: 7006663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):823-30. PubMed ID: 7006664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
    Cuzick J; De Stavola BL; Cooper EH; Chapman C; MacLennan IC
    Br J Haematol; 1990 Aug; 75(4):506-10. PubMed ID: 2119793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults.
    MacLennan IC; Cusick J
    Br J Cancer; 1985 Aug; 52(2):153-8. PubMed ID: 3896288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report on the first myelomatosis trial. I. Analysis of presenting features of prognostic importance.
    Br J Haematol; 1973 Jan; 24(1):123-39. PubMed ID: 4805842
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic factors in multiple myeloma in a population-based trial.
    Hannisdal E; Kildahl-Andersen O; Grøttum KA; Lamvik J
    Eur J Haematol; 1990 Oct; 45(4):198-202. PubMed ID: 2226737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelomatosis: comparison of melphalan and cyclophosphamide therapy.
    Br Med J; 1971 Mar; 1(5750):640-1. PubMed ID: 4926948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
    Rapoport BL; Falkson HC; Falkson G
    S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults.
    Cuzick J; Erskine S; Edelman D; Galton DA
    Br J Cancer; 1987 May; 55(5):523-9. PubMed ID: 3300761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic variables and clinical staging in multiple myeloma.
    Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
    Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults.
    Br Med J (Clin Res Ed); 1984 May; 288(6428):1411-6. PubMed ID: 6326927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A progress report on the Medical Research Council's therapeutic trial in myelomatosis.
    Galton DA; Peto R
    Br J Haematol; 1968 Sep; 15(3):319-20. PubMed ID: 5696221
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitoring myelomatosis.
    Hobbs JR
    Arch Intern Med; 1975 Jan; 135(1):125-30. PubMed ID: 1111461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients.
    Ferrigno D; Buccheri G
    Monaldi Arch Chest Dis; 2003; 59(3):193-8. PubMed ID: 15065314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
    Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
    Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing the prognosis in myelomatosis.
    Dawson AA; Ogston D
    Postgrad Med J; 1971 Oct; 47(552):635-8. PubMed ID: 5158835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of the serum phosphorus level and its relationship with other prognostic factors in multiple myeloma.
    Umeda M; Okuda S; Izumi H; Nagase D; Fujimoto Y; Sugasawa Y; Arai C; Natori K; Katoh M; Kuraishi Y
    Ann Hematol; 2006 Jul; 85(7):469-73. PubMed ID: 16528526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.